Data Sheet (Cat.No.T32923)

TargetMol

Lucerastat

Chemical Properties



CAS No. : 141206-42-0

Formula: C10H21NO4

Molecular Weight: 219.28

Storage: Keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Lucerastat（NBDGJ） is an orally available inhibitor of Glucosylceramide Synthase (GCS) with therapeutic potential for Fabry disease. GCS is a key enzyme in sphingolipid synthesis and inhibition of its activity reduces the accumulation of harmful substrates.
Targets(IC50)	Transferase

Solubility Information

Solubility	DMSO: 20 mg/mL (91.21 mM),Sonication is recommended. H2O: 20 mg/mL (91.21 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	4.5604 mL	22.8019 mL	45.6038 mL
5 mM	0.9121 mL	4.5604 mL	9.1208 mL
10 mM	0.456 mL	2.2802 mL	4.5604 mL
50 mM	0.0912 mL	0.456 mL	0.9121 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Takai T, et al. A bicyclic 1-deoxygalactonojirimycin derivative as a novel pharmacological chaperone for GM1 gangliosidosis. Mol Ther. 2013 Mar;21(3):526-32. doi: 10.1038/mt.2012.263. Epub 2013 Jan 22.
Kato T, et al. Novel method for chase analysis of oligosaccharide metabolic error caused by xenobiotics. Anal Biochem. 2010 Oct 1;405(1):103-8.
Kato A, et al. 2,5-Dideoxy-2,5-imino-d-altritol as a new class of pharmacological chaperone for Fabry disease. Bioorg Med Chem. 2010 Jun 1;18(11):3790-4.
Gerrard G, et al. Glucosylceramide synthase inhibitors sensitise CLL cells to cytotoxic agents without reversing P-gp functional activity. Eur J Pharmacol. 2009 May 1;609(1-3):34-9.